Recent Articles

Trials Produce Practice-Changing Results for Brain Cancer

| May 5, 2017 | 0 Comments

Trials Produce Practice-Changing Results for Brain Cancer Results from two clinical trials show that treating patients with the chemotherapy drug temozolomide in addition to radiation therapy increased overall and progression-free survival.See Original Article Study Forecasts ‘Silver Tsunami’ of Cancer Survivors According to an NCI study, the number of older cancer survivors will grow substantially over […]

Continue Reading

Nanoparticles Create Effective CAR T Cells in Living Mice

| May 5, 2017 | 0 Comments

Nanoparticles Create Effective CAR T Cells in Living Mice Researchers have developed a method to genetically engineer cancer-fighting immune cells in living animals using nanoparticles that carry DNA. The new study shows that the resulting immune cells, known as CAR T cells, eliminated leukemia in mice.See Original Article

Continue Reading

Immune-Cell Traps May Aid Cancer Metastasis

| May 4, 2017 | 0 Comments

Immune-Cell Traps May Aid Cancer Metastasis Cancer cells may exploit a normal function of neutrophils, the most common form of white blood cell, to help form metastatic tumors, a new study suggests.See Original Article Avelumab Induces Sustained Tumor Responses in Some Patients with Rare Skin Cancer In a phase II clinical trial, some patients with […]

Continue Reading

Patient-Derived Antibody Appears to Selectively Target Tumor Cells, Spur Immune Attack

| May 2, 2017 | 0 Comments

Patient-Derived Antibody Appears to Selectively Target Tumor Cells, Spur Immune Attack The CFH antibodies killed tumor cells in cell lines of several cancer types and slowed tumor growth in mouse models of brain and lung cancer, without evidence of side effects. See Original Article New Therapy Benefits Patients with Neuroendocrine Tumors Results from a clinical […]

Continue Reading

Olaratumab Approved to Treat Advanced Soft Tissue Sarcoma

| May 1, 2017 | 0 Comments

Olaratumab Approved to Treat Advanced Soft Tissue Sarcoma The Food and Drug Administration (FDA) has granted accelerated approval to olaratumab (Lartruvo®) for the treatment of some patients with soft tissue sarcoma. See Original Article Study Shows Platelets Can Deliver Immunotherapy, Reduce Tumor Regrowth In experiments in mice, researchers show platelets linked to an immunotherapy drug […]

Continue Reading

Patients Who Choose No Intervention for Small Thyroid Cancers Report Lack of Support

| April 27, 2017 | 0 Comments

Patients Who Choose No Intervention for Small Thyroid Cancers Report Lack of Support Patients who choose not to pursue immediate biopsy or treatment for small, asymptomatic thyroid cancers, or suspected cancers, can experience a lack of support from doctors and loved ones, a new study shows.See Original Article

Continue Reading

Program Spotlight: Training Navigation

| April 26, 2017 | 0 Comments

Program Spotlight: Training Navigation Dr. Hana Odeh talks about CRCHD’s new training navigation initiative and her role as training navigator. See Original Article

Continue Reading

PARP Inhibitors May Be Effective in Brain, Other Cancers with IDH Mutations

| April 24, 2017 | 0 Comments

PARP Inhibitors May Be Effective in Brain, Other Cancers with IDH Mutations Studies presented at the 2017 AACR annual meeting suggest that therapies which take advantage of the mutations in the IDH gene may be more effective than drugs that block it.See Original Article

Continue Reading

Making Greater Progress Against Cancer—Not Just a Hope but a Reality

| April 21, 2017 | 0 Comments

Making Greater Progress Against Cancer—Not Just a Hope but a Reality Acting NCI Director Dr. Doug Lowy discusses what he calls encouraging news in the most recent Annual Report to the Nation and how NCI is helping to achieve further progress against cancer.See Original Article

Continue Reading

New Treatment Target Identified for Key Prostate Cancer Driver

| April 19, 2017 | 0 Comments

New Treatment Target Identified for Key Prostate Cancer Driver Researchers have identified a potential alternative approach to blocking a key molecular driver of an advanced form of prostate cancer, called androgen-independent or castration-resistant prostate cancer.See Original Article The Moonshot Blue Ribbon Panel: Moving Toward a Final Report An update on the activities of the National […]

Continue Reading